

# Stanley Lipkowitz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5316709/publications.pdf>

Version: 2024-02-01

51  
papers

4,813  
citations

147801

31  
h-index

189892

50  
g-index

53  
all docs

53  
docs citations

53  
times ranked

7895  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Rare Breast Cancer Subtypes. <i>Current Oncology Reports</i> , 2021, 23, 54.   | 4.0  | 15        |
| 2  | In Vitro Ubiquitination Platform Identifies Methyl Ellipticiniums as Ubiquitin Ligase Inhibitors. <i>SLAS Discovery</i> , 2021, 26, 870-884.   | 2.7  | 5         |
| 3  | Sequential ubiquitination of NLRP3 by RNF125 and Cbl-b limits inflammasome activation and endotoxemia. <i>Journal of Experimental Medicine</i> , 2020, 217, .  | 8.5  | 90        |
| 4  | Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. <i>Clinical Cancer Research</i> , 2020, 26, 4268-4279.   | 7.0  | 126       |
| 5  | Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. <i>Future Oncology</i> , 2020, 16, 899-909.  | 2.4  | 22        |
| 6  | A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in <i>BRCA</i> Wild-Type, Advanced Triple-Negative Breast Cancer. <i>Oncologist</i> , 2020, 25, 1013-e1824.  | 3.7  | 40        |
| 7  | Loss of function Cbl-c mutations in solid tumors. <i>PLoS ONE</i> , 2019, 14, e0219143.  | 2.5  | 10        |
| 8  | Cbl interacts with multiple E2s in vitro and in cells. <i>PLoS ONE</i> , 2019, 14, e0216967.   | 2.5  | 15        |
| 9  | Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 207-215.   | 10.7 | 167       |
| 10 | Analysis of breast cancer in young women in the Department of Defense (DOD) database. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 501-511.  | 2.5  | 17        |
| 11 | ONC201 kills breast cancer cells<i>in vitro</i>by targeting mitochondria. <i>Oncotarget</i> , 2018, 9, 18454-18479.  | 1.8  | 77        |
| 12 | Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells. <i>Molecular Pharmaceutics</i> , 2017, 14, 1047-1056.  | 4.6  | 21        |
| 13 | Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2193-2202. | 1.6  | 209       |
| 14 | Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. <i>Oncotarget</i> , 2017, 8, 79175-79187.  | 1.8  | 32        |
| 15 | Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation. <i>Cancer Research</i> , 2016, 76, 561-571.   | 0.9  | 38        |
| 16 | Mathematical models of breast and ovarian cancers. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2016, 8, 337-362.  | 6.6  | 19        |
| 17 | The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 235-251.   | 2.5  | 18        |
| 18 | New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. <i>Cancer Treatment Reviews</i> , 2016, 45, 87-96.  | 7.7  | 183       |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | ONC201: Stressing tumors to death. <i>Science Signaling</i> , 2016, 9, fs1.   | 3.6  | 22        |
| 20 | Molecular Pathways: Cbl Proteins in Tumorigenesis and Antitumor Immunity—Opportunities for Cancer Treatment. <i>Clinical Cancer Research</i> , 2015, 21, 1789-1794.                       | 7.0  | 81        |
| 21 | TIC10/ONC201: a bend in the road to clinical development. <i>Oncoscience</i> , 2015, 2, 75-76.  | 2.2  | 15        |
| 22 | Enigma Prevents Cbl-c-Mediated Ubiquitination and Degradation of RETMEN2A. <i>PLoS ONE</i> , 2014, 9, e87116.   | 2.5  | 21        |
| 23 | E3 Ubiquitin Ligase Cbl-b Suppresses Proallergic T Cell Development and Allergic Airway Inflammation. <i>Cell Reports</i> , 2014, 6, 709-723.   | 6.4  | 56        |
| 24 | Recruitment of Cbl-b to B Cell Antigen Receptor Couples Antigen Recognition to Toll-Like Receptor 9 Activation in Late Endosomes. <i>PLoS ONE</i> , 2014, 9, e89792.                      | 2.5  | 16        |
| 25 | Cbl as a Master Regulator of Receptor Tyrosine Kinase Trafficking. , 2013, , 219-244.   |      | 4         |
| 26 | Cbl exposes its RING finger. <i>Nature Structural and Molecular Biology</i> , 2012, 19, 131-133.  | 8.2  | 18        |
| 27 | WEE1 Inhibition Sensitizes Basal Breast Cancer Cells to TRAIL-Induced Apoptosis. <i>Molecular Cancer Research</i> , 2012, 10, 75-85.  | 3.4  | 30        |
| 28 | E3 Ubiquitin Ligase Cbl-b Regulates Pten via Nedd4 in T Cells Independently of Its Ubiquitin Ligase Activity. <i>Cell Reports</i> , 2012, 1, 472-482.                                     | 6.4  | 70        |
| 29 | Cbl-c Ubiquitin Ligase Activity Is Increased via the Interaction of Its RING Finger Domain with a LIM Domain of the Paxillin Homolog, Hic 5. <i>PLoS ONE</i> , 2012, 7, e49428.           | 2.5  | 18        |
| 30 | ARAP1 association with CIN85 affects epidermal growth factor receptor endocytic trafficking. <i>Biology of the Cell</i> , 2011, 103, 171-184.   | 2.0  | 19        |
| 31 | RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. <i>Nature Reviews Cancer</i> , 2011, 11, 629-643.                          | 28.4 | 347       |
| 32 | Triple negative breast cancer cell lines: One tool in the search for better treatment of triple negative breast cancer. <i>Breast Disease</i> , 2011, 32, 35-48.                          | 0.8  | 518       |
| 33 | Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 347-357.  | 2.5  | 77        |
| 34 | CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases. <i>PLoS ONE</i> , 2010, 5, e8972.  | 2.5  | 98        |
| 35 | Cbl and Human Myeloid Neoplasms: The Cbl Oncogene Comes of Age. <i>Cancer Research</i> , 2010, 70, 4789-4794.   | 0.9  | 116       |
| 36 | The N Terminus of Cbl-c Regulates Ubiquitin Ligase Activity by Modulating Affinity for the Ubiquitin-conjugating Enzyme. <i>Journal of Biological Chemistry</i> , 2010, 285, 23687-23698. | 3.4  | 35        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Chapter 3 The TRAIL to Targeted Therapy of Breast Cancer. <i>Advances in Cancer Research</i> , 2009, 103, 43-73.  | 5.0 | 71        |
| 38 | TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 217-230.  | 2.5 | 157       |
| 39 | 2-Methoxyestradiol Mediates Apoptosis Through Caspase-Dependent and Independent Mechanisms in Ovarian Cancer Cells But Not in Normal Counterparts. <i>Reproductive Sciences</i> , 2008, 15, 878-894.  | 2.5 | 25        |
| 40 | Structural Basis for Ubiquitin-Mediated Dimerization and Activation of the Ubiquitin Protein Ligase Cbl-b. <i>Molecular Cell</i> , 2007, 27, 474-485.   | 9.7 | 107       |
| 41 | TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2007, 12, 73-85.   | 4.9 | 34        |
| 42 | Regulating the regulator: negative regulation of Cbl ubiquitin ligases. <i>Trends in Biochemical Sciences</i> , 2006, 31, 79-88.  | 7.5 | 88        |
| 43 | Gefitinib response of erlotinib-refractory lung cancer involving meninges' role of EGFR mutation. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 50-57.  | 4.3 | 114       |
| 44 | CIN85 Participates in Cbl-b-mediated Down-regulation of Receptor Tyrosine Kinases. <i>Journal of Biological Chemistry</i> , 2002, 277, 39666-39672.   | 3.4 | 108       |
| 45 | Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells. <i>Oncogene</i> , 2002, 21, 1423-1433.   | 5.9 | 24        |
| 46 | Biomarker Assays in Nipple Aspirate Fluid. <i>Breast Journal</i> , 2001, 7, 378-387.  | 1.0 | 38        |
| 47 | The Death Domain Kinase RIP Is Essential for TRAIL (Apo2L)-Induced Activation of I $\kappa$ B Kinase and c-Jun N-Terminal Kinase. <i>Molecular and Cellular Biology</i> , 2000, 20, 6638-6645.  | 2.3 | 224       |
| 48 | Tyrosine phosphorylation and complex formation of Cbl-b upon T cell receptor stimulation. <i>Oncogene</i> , 1999, 18, 1147-1156.  | 5.9 | 72        |
| 49 | Ubiquitin Ligase Activity and Tyrosine Phosphorylation Underlie Suppression of Growth Factor Signaling by c-Cbl/Sli-1. <i>Molecular Cell</i> , 1999, 4, 1029-1040.  | 9.7 | 912       |
| 50 | cbl-b Inhibits EGF-Receptor-Induced Apoptosis by Enhancing Ubiquitination and Degradation of Activated Receptors. <i>Molecular Cell Biology Research Communications: MCBRC: Part B of Biochemical and Biophysical Research Communications</i> , 1999, 2, 111-118. | 1.6 | 48        |
| 51 | Serine Phosphorylation of Cbl Induced by Phorbol Ester Enhances Its Association with 14-3-3 Proteins in T Cells via a Novel Serine-rich 14-3-3-binding Motif. <i>Journal of Biological Chemistry</i> , 1997, 272, 9979-9985.                                      | 3.4 | 126       |